Latest Insider Transactions at Deciphera Pharmaceuticals, Inc. (DCPH)
This section provides a real-time view of insider transactions for Deciphera Pharmaceuticals, Inc. (DCPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Deciphera Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Deciphera Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
72,261
-100.0%
|
-
|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,029
-49.92%
|
-
|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,157
+19.14%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,478
-100.0%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,029
-62.9%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,157
+22.98%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
34,243
-100.0%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
53,951
-61.17%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,163
+18.61%
|
-
|
|
Jun 11
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
184,088
-100.0%
|
-
|
|
Jun 11
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,913
+12.34%
|
-
|
|
Jun 11
2024
|
Franklin Stuart Friedman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
31,330
-100.0%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,951
-58.38%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,163
+21.13%
|
-
|
|
Jun 11
2024
|
Dennis Leo Walsh |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,000
-100.0%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
72,763
-100.0%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
286,075
-79.72%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
286,075
+44.36%
|
-
|
|
Apr 22
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
48,136
+0.21%
|
$0
$0.01 P/Share
|
|
Feb 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.95%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.22%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,010
-3.61%
|
$45,150
$15.62 P/Share
|
|
Feb 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,615
-2.35%
|
$39,225
$15.62 P/Share
|
|
Feb 15
2024
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,725
+14.49%
|
-
|
|
Feb 15
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+9.85%
|
-
|
|
Feb 15
2024
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,725
+13.17%
|
-
|
|
Feb 15
2024
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+17.17%
|
-
|
|
Feb 15
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+13.43%
|
-
|
|
Feb 07
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
914,001
+3.81%
|
$0
$0.01 P/Share
|
|
Jan 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.3%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,435
-3.55%
|
$34,090
$14.47 P/Share
|
|
Jan 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.11%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,435
-2.52%
|
$34,090
$14.47 P/Share
|
|
Dec 13
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,792
-2.81%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,727
-3.39%
|
$25,905
$15.37 P/Share
|
|
Dec 13
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,662
-3.09%
|
$24,930
$15.37 P/Share
|
|
Dec 13
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,792
-3.92%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
30,664
-29.65%
|
$459,960
$15.37 P/Share
|
|
Dec 12
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+7.67%
|
-
|
|
Dec 12
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+9.85%
|
-
|
|
Dec 12
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+9.38%
|
-
|
|
Dec 12
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+10.36%
|
-
|
|
Dec 12
2023
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+37.67%
|
-
|
|
Nov 30
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,801
-28.15%
|
$213,612
$12.57 P/Share
|
|
Oct 30
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.19%
|
$16,884
$12.02 P/Share
|
|
Oct 30
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.83%
|
$16,884
$12.02 P/Share
|
|
Oct 30
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,360
-2.54%
|
$28,320
$12.02 P/Share
|
|
Oct 30
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
21,573
-34.52%
|
$258,876
$12.02 P/Share
|
|
Oct 30
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,316
-3.54%
|
$27,792
$12.02 P/Share
|